Omeprazole Market Size & Share, by Dosage Form (Capsule, Tablet, Powder); Distribution Channel (Hospital, Retail, Online); Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux, Erosive Esophagitis) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2477
  • Published Date: Sep 05, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Omeprazole Market size is poised to cross USD 4 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of omeprazole was over USD 1 Billion. Increasing cases of chronic diseases globally are boosting market growth. As per a report generated by WHO, at the end of 2050 chronic diseases such as cancer, diabetes, and respiratory ailments will be responsible for a startling 90% of all global fatalities.

Positive results during the clinical trials of omeprazole in H. pylori elimination therapy are anticipated to increase the demand for omeprazole globally during the foreseen period. In order to treat Helicobacter pylori infection, RedHill Biopharma, for example, recently published the phase 3 findings of the Talicia capsule, which combines antibiotics and a proton pump inhibitor.


Omeprazole Market
Get more information on this report: Request Free Sample PDF

Omeprazole Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Cases of Gastroesophageal Reflux Omeprazole is a prescribed proton pump inhibitor (PPI) that aids in reducing acidity. Due to its effective results, this drug has been approved by regulatory agencies in order to cure heartburns as well as for the treatment of gastroesophageal reflux. Apart from the elderly population gastroesophageal reflux can affect youngsters as well which is boosting the growth of the omeprazole market. According to El-Serag et al.'s systematic review, gastroesophageal reflux prevalence in the US ranges from 18.1% to 27.8%.
  • Increasing Awareness among People- Increasing awareness among people for the treatment of gastrointestinal diseases is also expected to drive market growth. For example, the International Foundation for Functional Gastrointestinal Disorders, a not-for-profit educational and research organization, helps improve the lives of people with chronic digestive disorders. The IFFGD enhances knowledge, supports research, and improves the education of individuals.
  • Increasing prevalence of Duodenal Ulcers – An increasing number of patients who are suffering from peptic ulcers are in increased need of the treatment of the disease using the Omeprazole drug. Also, as per a report by Virtual Medical Centre, the most common disease in the world is peptic ulcer, around 10-15% of the population is affected globally. Men and the elderly population generally suffer from peptic ulcers. This factor is bolstering the market growth rapidly.

Challenges

  • Increasing Alternative Drugs – Pantoprazole, lansoprazole, and esomeprazole are some of the alternative drugs of Omeprazole which are used widely around the world. Due to these alternatives in the market, the growth of the omeprazole market is expected to be hampered.
  • Side Effects of the Drug
  • Higher Cost of the Drug

Omeprazole Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~ 6%

Base Year Market Size (2022)

~ USD 1 Billion

Forecast Year Market Size (2035)

~ USD 4 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Omeprazole Segmentation

Dosage Form (Capsule, Tablet, Powder)

The capsule segment is expected to propel the omeprazole market growth in the forecast period. The capsule segment is expected to occupy 52% of the largest market share by 2035. Additionally, the capsule is expected to cross 1800 Million by the end of 2035. The tablets are easy to handle and inexpensive. Also, 2020 will see a 24% increase in total medication use to 4.5 trillion doses. More than half of the world's population will take more than one dose of medication per person per day, up from one-third in 2005, with India, China, Brazil, and Indonesia leading the way. This may result in the expansion of industry growth.

Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux, Erosive Esophagitis)

The duodenal ulcer category is expected to drive market growth. This category was leading the market in 2019 as well. Duodenal ulcers are most commonly observed in the age groups of 25-55 years. With age, the incidence of peptic ulcer increased to a peak of 28.8% in the 5th decade of life. Duodenal ulcers are thought to affect 5 to 15% of people in the West, according to numerous studies that have assessed their prevalence. These factors are driving the growth of this segment. 

Our in-depth analysis of the global market includes the following segments:

     Dosage Form

  • Capsule
  • Tablet
  • Powder

     Distribution Channel

  • Hospital
  • Retail
  • Online

     Indication

  • Duodenal Ulcer
  • Gastric Ulcer
  • Gastroesophageal Reflux
  • Erosive Esophagitis

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Omeprazole Industry - Regional Synopsis

North American Market Forecast

North America omeprazole market is anticipated to hold the largest share of 59.3% during the forecast period. In 2020 the region experienced the prevalence of H. pylori infection which causes ulcers. Additionally, peptic ulcers are prominent in the US, around 4.5 million individuals are affected yearly. Also, about 10% of the US population is affected by duodenal ulcers. For example, there is an online service that helps people save around 80% on their prescription costs by working with large pharmacies in the US. These key factors are bolstering the market growth of Omeprazole in the region.

APAC Market Statistics

Asia Pacific to hold a share of 28.6% by 2035. Market growth in the region is driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key market players to increase their product portfolio. Vonoprazan, a product that is FDA-cleared for the treatment of gastroesophageal reflux disease by Phantom Pharmaceutics, was made available to Japanese consumers and another Asian country in March 2022. In addition, with the increased demand for gastroesophageal disease treatment in the Asia region, a number of players have been expanding their presence there.

Research Nester
Omeprazole Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Omeprazole Landscape

top-features-companies
    • Boehringer Ingelheim
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AstraZeneca Plc.
    • Azurity Pharma
    • Perrigo Company Plc.
    • Salix pharmaceuticals

In-the-news

In The News

  • Perrigo Company, a leading supplier of consumer health products announces today that the US Food and Drug Administration has given final clearance for omeprazole magnesium delayed mini capsules, 20mg OTC. Perrigo is planning to make Omeprazole Minis available in the latter part of this year.
  • AstraZeneca announced to sell omeprazole and its associated brand's global commercial rights to Cheplapharm Arzneimittel GmbH.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2477
  • Published Date: Sep 05, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing cases of gastroesophageal reflux, increasing awareness among people, and increasing prevalence of duodenal ulcers.

The market size of omeprazole is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Boehringer Ingelheim, AstraZeneca Plc., Azurity Pharma, Perrigo Company Plc, Salix Pharmaceuticals, Mochida Pharmaceutical Co., Ltd., Yoshindo Inc, Fuji Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Takeda Pharmaceuticals Co., Ltd and others.

The capsule segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Omeprazole Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying